BIOLOGICAL IMPACT OF METFORMIN VERSUS THIAZOLIDINEDIONE ON ALVEOLAR BONE OF INDUCED DIABETIC RATS (A HISTOLOGICAL AND IMMUNO-HISTOMORPHOMETRIC STUDY).

  • Lecturer of Oral and Dental Biology, Faculty of Dental Medicine for girls, Al-Azhar University, Cairo-Egypt.
  • Assistant Prof. of Oral and Dental Biology, Faculty of Dental Medicine for girls, Al-Azhar University, Cairo-Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • How to Cite This Article
  • Corresponding Author

Objective: To evaluate how the most currently used anti-diabetic drugs (pioglitazone & metformin) can secondarily affect diabetic alveolar bone. Materials and methods: 70 adult male rats (170?200 g) were obtained. Diabetes was induced in 60 animals by intraperitoneal administration of nicotinamide (NA) (270 mg/kg) 15 min before IV administration of STZ (65 mg/kg). The rats were divided into four groups: Control; Group (I): composed of 10 rats without diabetes. Experimental groups; Group (II) composed of 20 diabetic rats. Group (III): 20 diabetic rats received pioglitazone (4 mg/kg/day). Group (IV): composed of 20 diabetic rats received metformin (250 mg/kg/day). By the end of the experimental period (4 weeks), all rats were sacrificed. The mandibles specimens were processed for histological examination and immunostained by Osteoprotogrin for immunohistomorphometry. Results: The histological results in (group IV) revealed minimal osteoporotic features of alveolar bone in relation to (group III) that showed an obvious deterioration of the alveolar bone. Immunohistochemical results showed mild to strong stained areas in group (IV) and negative immune-stain for all regions except for few areas appeared with very mild stain in group (III). Statistical analysis revealed that no significant difference between group I and group IV. Moreover, the difference between group IV and groups II and III was significant. Conclusion: Our result stands as a source of data regarding the in vivo superior influence of anti-diabetic drug Metformin versus Thiazolidinedione (Pioglitazone) on diabetic alveolar bone health by its inhibitory effect on diabetic bone loss.

  1. Adami S (2009) ?Bone health in diabetes: considerations for clinical management?. Current medical research and opinion. ?25:1057-1072. doi: 10.1185/03007990902801147
  2. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL.(2005) ?Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.? 146(3):1226-1235.doi:10.1210/en.2004-0735
  3. Bacevic M ,?Brkovic B ,?Albert A ,?Rompen E ,?Radermecker RP, ?Lambert F ?(2017) ?Does Oxidative Stress Play a Role in Altered Characteristics of Diabetic Bone? A Systematic Review.? Calcif Tissue Int. 101(6):553-563. doi: 10.1007/s00223-017-0327-7
  4. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. (2007)?Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin? Diabetes Care.30(4):890-895. doi:2337/dc06-1732
  5. Coetzee M & Kruger MC (2004) ?Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?? South Med J.97(5):506-511.
  6. Consoli A& Formoso G. (2013) ?Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus??Diabetes Obes Metab. 15(11):967-977. ?doi: 10.1111/dom.12101
  7. Dobnig H, Piswanger-solkner JC and Roth M. (2006) ?Type 2 diabetes mellitus in nursing home patients: effects on bone turn over, bone mass, and fracture risk?. clin. endocrinol.metab.91:3355-3363. doi:10.1210/jc.2006-0460
  8. Gao Y,?Li Y,?Xue J,?Jia Y,?Hu J. (2010) ?Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats.? Eur J Pharmacol.10;635(1-3):231-236. oi: 10.1016/j.ejphar.2010.02.051.
  9. Gilbert MP and Pratley RE. (2015) ?The impact of diabetes and diabetes medications on bone health? Endocr Rev. Apr; 36(2):194-213. doi: 10.1210/er.2012-1042.
  10. Gilbert MP, Pratley RE. (2015) ?The impact of diabetes and diabetes medications on bone health.? Endocr Rev. 36(2):194-213. doi:1210/er.2012-1042
  11. Hauner H. (2002) ?The mode of action of thiazolidinediones.? Diabetes Metab Res Rev.18 (2):10-15.
  12. Hoda W.El Gawly, Mona K.Tawfik, Maha F. Rashwan, Ali S. Baruzaig.(2009) ?The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino wistar rats. Eur Rev Med Pharmacol Sci. 13: 443-451
  13. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. (2015) ?Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.? Diabetes Care.38 (1):140-149.
  14. Jeyabalan J,?Viollet B,?Smitham P,?Ellis SA,?Zaman G,?Bardin C,?Goodship A,?Roux JP,?Pierre M,?Chenu C. (2013) ?The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing.? Osteoporos Int.?24(10):2659- 26570. doi: 10.1007/s00198-013-2371-0.
  15. Kasai T, Bandow K, Suzuki H, Chiba N, Kakimoto K, Ohnishi T, Kawamoto S, Nagaoka E, Matsuguchi .T (2009) ?Osteoblast differentiation is functionally associated with decreased AMP kinase activity.?J Cell Physiol. 221(3):740-749. doi: 10.1002/jcp.21917.
  16. Kim JH, Lee DE, Choi SH, Cha JH, Bak EJ, Yoo YJ. (2014) ?Diabetic characteristics and alveolar bone loss in streptozotocin- and streptozotocin-nicotinamide-treated rats with periodontitis?. J Periodontal Res. 49(6):792-800. doi: 10.1111/jre.12165
  17. Kostenuik PJ ,?Shalhoub V. (2001) ?Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.? Curr Pharm Des.7(8):613-635.
  18. Lane NE,?Yao W,?Balooch M,?Nalla RK,?Balooch G,?Habelitz S,?Kinney JH,?Bonewald LF. (2006) ?Glucocorticoid-Treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in Placebo-treated or estrogen deficient mice.? Bone. Miner. Res., 21: 466-476. doi:10.1359/JBMR.051103
  19. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL (2002) ?Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation.? 143(6):2376-2384. doi:10.1210/endo.143.6.8834
  20. Leidig-Bruckner G ,?Grobholz S,?Bruckner T,?Scheidt-Nave C,?Nawroth P,?Schneider JG. (2014) ?Prevalence and determinants of?osteoporosis?in patients with type 1 and type 2?diabetes mellitus?.? Endocr Disord. 11;14:33. doi: 10.1186/1472-6823-14-33.
  21. Madsen A, Bozickovic O, Bjune JI, Mellgren G, Sagen JV (2015) ?Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2).? Sci Rep.9; 5:16430. doi: 10.1038/srep16430
  22. Mai QG,?Zhang ZM,?Xu S,?Lu M,?Zhou RP,?Zhao L,?Jia CH,?Wen ZH,?Jin DD,?Bai XC. (2011) ?Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats?. J Cell Biochem..?112 (10):2902-2909. doi: 10.1002/jcb.23206.
  23. Marycz K,?Tomaszewski KA,?Kornicka K,?Henry BM,?Wroński S,?Tarasiuk J,?Maredziak M (2016) ?Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells?In Vitro, and Increases Bone Density?In Vivo.? Oxid Med Cell Longev. 97858-90. doi: 10.1155/2016/9785890
  24. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. (1998) ?Experimental NIDDM: Development of a New Model in Adult Rats Administered Streptozotocin and Nicotinamide?.?47(2):?224-229.
  25. McCarthy AD, Cortizo AM, Sedlinsky CWorld (2016) ?Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?. Diabetes. 25; 7(6):122-33. ?doi: 10.4239/wjd.v7.i6.122.
  26. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B (2006) ?Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.? Diabetes Care; 29(8):1963. doi:2337/dc06-9912
  27. Nicodemus KK, and Folsom AR. (2001) ?Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women?. Diabetes care. 24:1192-7.
  28. Okonkwo P.O. and Okoye ZSC (2014) ?Comparative Effects of Antidiabetic Drug, Metformin and Deferoxamine, on Serum Lipids, Serum Ferritin and Endocrine Indicators of Diabetes Mellitus Complications in Sreptozotocin Diabetic Rats? International Journal of Biochemistry Research & Review. 4(6): 536-549,
  29. Rojas LB, ?Gomes MB (2013) ?Metformin: an old but still the best treatment for type 2 diabetes.? Diabetology & Metabolic Syndrome, 15; 5 (1):6. doi: 10.1186/1758-5996-5-6.
  30. Rubin MR. (2015) ?Bone cells and bone turnover in diabetes mellitus?. Curr Osteoporos 13(3):186-191. doi:10.1007/s11914-015-0265-0
  31. Schwartz AV (2017) ?Review?Diabetes, bone and glucose-lowering agents: clinical outcomes.? Diabetologia. Jul; 60(7):1170-1179. doi: 10.1007/s00125-017-4283-6.
  32. Szkudelski T, Zywert A, Szkudelska K. (2013) ?Metabolic disturbances and defects in insulin secretion in rats with streptozotocin-nicotinamide-induced diabetes.? Physiol.; 62(6):663-670.
  33. Szkudelski T. (2012) ?Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model.? Exp Biol Med (Maywood).237(5):481-490. doi: 10.1258/ebm.2012.011372
  34. Udagawa N,?Takahashi N,?Yasuda H,?Mizuno A,?Itoh K,?Ueno Y,?Shinki T,?Gillespie MT,?Martin TJ,?Higashio K,?Suda T.(2000) ?Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.? 141(9):3478-3484. Doi :10.1210/endo.141.9.7634
  35. Vestergaard P, Rejenmark L, Mosekilde L.(2005) ?Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk?. Diabetologia. 48: 1292-9. doi:1007/s00125-005-1786-3
  36. Vianna G. D., Sanches C. P. and? Barreto. F. C (2017) ?Effects of type 2 diabetes therapies on bone metabolism. Diabetol Metab Syndr. 9: 75. ?doi: 10.1186/s13098-017-0274-5
  37. Viviana Lacava, Vincenzo Pellican?, Carmen Ferrajolo, Valeria Cernaro, Luca Visconti, Giovanni Conti (2017) ?Novel avenues for treating diabetic nephropathy: new investigational drugs.? Journal of Expert Opinion on Investigational Drugs 26:445-462.doi: 10.1080/13543784.2017.1293039.
  38. Xue Han , Yu-Long Tao, Ya-Ping Deng , Jia-Wen Yu , Jian Cai , Guo-Fei Ren and Yuan-Nan Sun, Guo-Jun Jiang (2017) ?Metformin ameliorates insulitis in STZ induced diabetic mice?. Peer J. ?doi: 10.7717/peerj.3155.
  39. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, Bollag WB, Bollag RJ, Hamrick M, Insogna K, Isales CM. (2007) ?Effects of glucose-dependent insulinotropic peptide on osteoclast function.? Am J Physiol Endocrinol Metab. 292?(2),?543-548. doi:1152/ajpendo.00364.2006.

Marwa A. M. El-Shiekh and Heba A. Adawy. (2017); BIOLOGICAL IMPACT OF METFORMIN VERSUS THIAZOLIDINEDIONE ON ALVEOLAR BONE OF INDUCED DIABETIC RATS (A HISTOLOGICAL AND IMMUNO-HISTOMORPHOMETRIC STUDY)., Int. J. of Adv. Res., 5 (11), 808-817, ISSN 2320-5407. DOI URL: https://dx.doi.org/10.21474/IJAR01/5834

Marwa Abdel Mohsen El Shiekh
* Lecturer of Oral and Dental Biology, Faculty of Dental Medicine for girls, Al-Azhar University, Cairo-Egypt.

DOI:

Article DOI: 10.21474/IJAR01/5834      
DOI URL: https://dx.doi.org/10.21474/IJAR01/5834

Download Full Paper

Download PDF No. of Downloads: 10 | No. of Views: 75